
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>An Evidence-Based Practical Review on Common Benign Anorectal Disorders: Hemorrhoids, Anal Fissure, Dyssynergic Defecation, and Fecal Incontinence</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "â–¶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>An Evidence-Based Practical Review on Common Benign Anorectal Disorders: Hemorrhoids, Anal Fissure, Dyssynergic Defecation, and Fecal Incontinence</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Gastroenterology</li><li>- <b>Publication Date:</b> Available online 14 November 2025</li><li>- <b>DOI:</b> https://doi.org/10.1053/j.gastro.2025.07.031</li></ul>
                
        <details>
            <summary><strong>ðŸ’¡ Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recurrence rate of hemorrhoids after stapled hemorrhoidopexy compared to excisional hemorrhoidectomy in a large RCT?</li><li>- What is the recommended first-line topical therapy for chronic anal fissures according to ASCRS guidelines?</li><li>- In patients with dyssynergic defecation, what percentage of individuals show clinically significant variability in the rectoanal gradient on different days?</li><li>- What is the long-term success rate (â‰¥50% reduction in FI episodes) of Sacral Neuromodulation (SNM) at 5-10 years?</li><li>- What is the healing rate of chronic anal fissures with Lateral Internal Anal Sphincterotomy (LIS)?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hemorrhoids</strong></summary>
            <div>
                <ul><li>- Normal variations of the inferior hemorrhoidal plexus (anal cushions) contributing to the anal barrier.</li><li>- The <u>third most common</u> outpatient gastrointestinal diagnosis in the United States.</li></ul>
                
        <details>
            <summary><strong>Classification & Pathophysiology</strong></summary>
            <div>
                <ul><li>- <b>Internal Hemorrhoids:</b> Originate <u>above</u> the dentate line, covered with rectal columnar epithelium.</li><li>- <b>External Hemorrhoids:</b> Originate <u>below</u> the dentate line, covered by anoderm and skin.</li></ul>
                
        <details>
            <summary><strong>Locations</strong></summary>
            <div>
                <ul><li>- Internal hemorrhoids primarily occur in the <q>right anterior, right posterior, and left lateral</q> locations.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- Deterioration of anchoring connective tissue due to age, straining, or pregnancy causes hemorrhoids to bulge and descend.</li><li>- Association with <u>diarrhea</u> has been noted in some studies, challenging the traditional link to only constipation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Features & Grading</strong></summary>
            <div>
                <ul><li>- Symptoms vary by grade and presence of complications.</li></ul>
                
        <details>
            <summary><strong>Grading of Internal Hemorrhoids (See Figure 1)</strong></summary>
            <div>
                <ul><li>- <b>Stage I:</b> Cause bleeding but <u>do not prolapse</u>.</li><li>- <b>Stage II:</b> Prolapse beyond the anal margin but <u>reduce spontaneously</u>.</li><li>- <b>Stage III:</b> Prolapse requires <u>manual reduction</u>.</li><li>- <b>Stage IV:</b> Prolapse is <u>irreducible</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>- <b>Bleeding:</b> Typically <u>bright red</u>, occurring after defecation.</li><li>- <b>Prolapse Symptoms:</b> Sensation of a lump, discomfort, difficulty wiping, mucous discharge, fecal seepage, pruritus ani.</li><li>- <b>Significant Pain:</b> Suggests <u>strangulation</u> or a <u>thrombosed external component</u>. Uncomplicated internal hemorrhoids are not painful.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>External Hemorrhoids</strong></summary>
            <div>
                <ul><li>- May thrombose, presenting as an <u>acutely painful lump</u> at the anal verge.</li><li>- Resolution may leave skin tags.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Visual inspection and digital rectal examination are key first steps.</li><li>- <u>Anoscopy</u> is used to diagnose internal hemorrhoids.</li></ul>
                
        <details>
            <summary><strong>Excluding Malignancy</strong></summary>
            <div>
                <ul><li>- Hemorrhoids should not be presumed to be the sole cause of bleeding.</li><li>- Perform <b>flexible sigmoidoscopy</b> or <b>colonoscopy</b> to exclude cancer, especially with alarm symptoms (blood mixed with stool, change in bowel habits, weight loss).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Differential Diagnosis for Acute Anal Pain</strong></summary>
            <div>
                <ul><li>- Main differentials: <q>anal fissure, perianal abscess, and thrombosed external hemorrhoids</q>.</li><li>- Severe unexplained pain warrants urgent examination under anesthesia.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Elective Treatment</strong></summary>
            <div>
                <ul><li>- Treatment is based on the grade of hemorrhoids and symptom severity (See Figure 1).</li></ul>
                
        <details>
            <summary><strong>Conservative Management</strong></summary>
            <div>
                <ul><li>- Appropriate for all grades, especially grades I-II.</li><li>- <b>High-fiber diet:</b> Improves symptoms and reduces bleeding.</li><li>- Other measures (sitz baths, proper hygiene, topical preparations) have scarce supporting evidence.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Phlebotonics</strong></summary>
            <div>
                <ul><li>- Plant-derived agents (e.g., diosmin, troxerutin) available as dietary supplements in the US.</li><li>- Cochrane Review showed improvement in: <b>bleeding</b> (OR, <q>0.12</q>), <b>pruritus</b> (OR, <q>0.23</q>), and <b>discharge/leakage</b> (OR, <q>0.12</q>).</li><li>- <u>No significant improvement in pain</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Office-Based Procedures</strong></summary>
            <div>
                <ul><li>- Next step for grades I-II, and some grade III hemorrhoids.</li></ul>
                
        <details>
            <summary><strong>Rubber Band Ligation (RBL)</strong></summary>
            <div>
                <ul><li>- Recommended for grades <q>I, II, and some III</q> hemorrhoids.</li><li>- Bands are placed at least <q><b>1â€“2 cm above the dentate line</b></q> to avoid somatic pain.</li><li>- Rare complications (<q>~1%</q>): severe bleeding (typically 3-14 days post-procedure), perianal sepsis, vasovagal reactions.</li></ul>
                
        <details>
            <summary><strong>Contraindications & Precautions</strong></summary>
            <div>
                <ul><li>- <b>Contraindicated</b> in patients on <q>warfarin</q> and those with <q>portal hypertension</q>.</li><li>- ASCRS recommends considering pausing antiplatelet/anticoagulation therapy after weighing risks.</li><li>- Relatively contraindicated in immunocompromised patients due to sepsis risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Procedures</strong></summary>
            <div>
                <ul><li>- <b>Sclerotherapy:</b> Common outside the US for grades I-II. Good short-term relief but <u>high recurrence rate</u>. Sclerosants are used off-label in the US.</li><li>- <b>Infrared Coagulation:</b> No significant difference in effectiveness compared to RBL, but RBL causes more post-op pain.</li><li>- <b>Bipolar Electrocoagulation:</b> RBL is <u>more effective</u> and requires fewer sessions.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surgical Treatment</strong></summary>
            <div>
                <ul><li>- Reserved for higher-grade hemorrhoids or failure of less invasive treatments.</li></ul>
                
        <details>
            <summary><strong>Excisional Hemorrhoidectomy</strong></summary>
            <div>
                <ul><li>- <u>Standard of care</u> for grade <q>IIIâ€“IV</q> internal hemorrhoids and mixed hemorrhoids.</li><li>- Offers excellent long-term outcomes with a much lower retreatment rate than RBL (RR, <q>0.20</q>).</li><li>- Associated with <u>significant postoperative pain</u> and higher complication rates.</li></ul>
                
        <details>
            <summary><strong>Post-op Pain Management</strong></summary>
            <div>
                <ul><li>- Best managed with a multimodal regimen including topical anesthetics and <q><b>diltiazem</b></q>.</li><li>- Oral metronidazole is <u>not superior to placebo</u> for post-hemorrhoidectomy pain.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Stapled Hemorrhoidopexy</strong></summary>
            <div>
                <ul><li>- Less postoperative pain and faster recovery than excisional hemorrhoidectomy.</li><li>- Associated with <u>higher long-term recurrence rates</u> (<q><b>32%</b></q> vs <q><b>14%</b></q> for excisional).</li><li>- Serious complications reported: rectovaginal fistula, rectal perforation, sepsis, and death.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Newer Procedures</strong></summary>
            <div>
                <ul><li>- Aim to avoid drawbacks of excisional surgery.</li></ul>
                
        <details>
            <summary><strong>Transanal Hemorrhoidal De-arterialization (THD)</strong></summary>
            <div>
                <ul><li>- Doppler-guided ligation of terminal branches of the superior rectal artery.</li><li>- Pooled recurrence rate was <q><b>17.5%</b></q> across 28 studies.</li><li>- 1-year recurrence was lower than RBL (<q>30%</q> vs <q>49%</q>) in one large RCT.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Radiofrequency Ablation (Rafaelo)</strong></summary>
            <div>
                <ul><li>- FDA-approved procedure.</li><li>- Meta-analysis reported a <q><b>4.8%</b></q> recurrence rate and a <q><b>17.6%</b></q> complication rate for grades II-III hemorrhoids.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Emergency Treatment</strong></summary>
            <div>
                <ul><li>- For acute, painful presentations.</li></ul>
                
        <details>
            <summary><strong>Thrombosed External Hemorrhoid</strong></summary>
            <div>
                <ul><li>- Most resolve with nonoperative management (sitz baths, stool softeners, topicals).</li><li>- <b>Surgical excision</b> (not just incision) should be considered if patient presents within <q><b>48â€“72 hours</b></q> of onset for immediate pain relief.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Strangulated Hemorrhoids</strong></summary>
            <div>
                <ul><li>- Caused by irreducible prolapse with vascular compromise.</li><li>- Requires <u>inpatient-based management</u> due to risk of gangrene and life-threatening infection.</li><li>- Treatment ranges from expectant management to emergency excisional surgery.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anal Fissure</strong></summary>
            <div>
                <ul><li>- A linear or oval break in the squamous epithelium of the distal anal canal.</li></ul>
                
        <details>
            <summary><strong>Characteristics & Pathophysiology</strong></summary>
            <div>
                <ul><li>- <b>Location:</b> Most common in the posterior midline (<q><b>85%â€“90%</b></q>) or anterior midline (<q><b>10%â€“15%</b></q>).</li><li>- <b>Symptoms:</b> Sharp, severe pain during and after defecation, with scant bright-red rectal bleeding.</li></ul>
                
        <details>
            <summary><strong>Acute vs. Chronic Fissure</strong></summary>
            <div>
                <ul><li>- <b>Acute:</b> Lasts <q><u>less than 6 weeks</u></q>; appears as a simple longitudinal tear.</li><li>- <b>Chronic:</b> Has additional features like raised edges, exposed internal sphincter fibers, external skin tags (sentinel piles), or internal hypertrophied anal papillae.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- Considered a nonhealing 'ischemic ulcer' due to increased sphincter tone and decreased anodermal blood flow.</li><li>- Posterior location is a watershed area for blood supply with less muscular support.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Diagnosis is made by <u>gentle inspection</u> of the anus.</li><li>- Digital rectal exam and anoscopy are often excruciatingly painful and should be avoided initially.</li></ul>
                
        <details>
            <summary><strong>Atypical Fissures</strong></summary>
            <div>
                <ul><li>- Off-midline fissures are atypical and require further investigation.</li><li>- Must be biopsied to rule out secondary causes like <q>Crohnâ€™s disease, HIV/AIDS, leukemia, or anal carcinoma</q>.</li><li>- An examination under anesthesia is necessary if a fissure is not visible or is off-midline.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Treatment approach differs for acute and chronic fissures.</li></ul>
                
        <details>
            <summary><strong>Acute Fissure Treatment</strong></summary>
            <div>
                <ul><li>- Most heal quickly with conservative measures.</li><li>- <b>Management:</b> Optimize bowel habits, warm sitz baths, topical anesthetic creams (e.g., lidocaine).</li><li>- Acute fissures should <u><b>not</b> be treated surgically</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Chronic Fissure Treatment (See Figure 2)</strong></summary>
            <div>
                <ul><li>- Usually requires intervention for healing and to prevent recurrence.</li></ul>
                
        <details>
            <summary><strong>First-Line: Topical Therapy</strong></summary>
            <div>
                <ul><li>- <b>Mechanism:</b> Reduce internal anal sphincter (IAS) tone to improve blood flow.</li><li>- <b>Agents:</b> Topical calcium channel blockers (CCBs) or nitrates (nitroglycerin).</li><li>- <b>ASCRS Recommendation:</b> <q><u>Topical calcium channel blockers</u></q> are first-line therapy.</li></ul>
                
        <details>
            <summary><strong>Efficacy & Side Effects</strong></summary>
            <div>
                <ul><li>- Nitroglycerin healing rates are <q>~60%</q> (vs 40% placebo).</li><li>- CCBs are at least as effective as nitroglycerin but with a much lower risk of headache (<q><b>7%</b></q> vs <q><b>56%</b></q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Second-Line: Botulinum Toxin (BT)</strong></summary>
            <div>
                <ul><li>- Considered if <q><b>8 weeks</b></q> of topical therapy fails.</li><li>- <b>Dose:</b> Typically <q>50â€“100 IU</q> injected into the IAS.</li><li>- <b>Efficacy:</b> Data is mixed and subsequent RCTs are less conclusive than early trials.</li><li>- <b>Recurrence:</b> High, with rates of <q>50% at 1 year</q> and <q>80% at 10 years</q> reported.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Third-Line: Lateral Internal Sphincterotomy (LIS)</strong></summary>
            <div>
                <ul><li>- The <u><b>gold standard operation</b></u> for chronic anal fissures when topical agents fail.</li><li>- <b>Healing Rate:</b> Approximately <q><b>90%</b></q>, one of the most effective operations in surgery.</li><li>- <b>Outcome:</b> Low recurrence and long-term continence is generally preserved.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dyssynergic Defecation (DD)</strong></summary>
            <div>
                <ul><li>- A condition characterized by uncoordinated muscle movements during attempted defecation.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Pathogenesis</strong></summary>
            <div>
                <ul><li>- Incidence is higher in women (<q>31.8 per 100,000</q>) than men (<q>6.6 per 100,000</q>).</li><li>- A substantial proportion of adults with laxative-refractory constipation have DD.</li></ul>
                
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- <b>Core Problem:</b> Inadequate rectal propulsive force and/or impaired anal relaxation during defecation.</li><li>- Most patients have both inadequate propulsion and pelvic floor spasticity.</li><li>- Risk factors include childhood trauma, abuse, anxiety, depression, opioids, Parkinson's disease, and diabetes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Features & Investigations</strong></summary>
            <div>
                <ul><li>- Symptoms like incomplete emptying, excess straining, and digitation are more predictive than stool frequency.</li><li>- Anorectal physiology tests are required for diagnosis as symptoms are not specific.</li></ul>
                
        <details>
            <summary><strong>Anorectal Manometry (ARM)</strong></summary>
            <div>
                <ul><li>- Measures anorectal pressures at rest, squeeze, and evacuation.</li><li>- <b>Key Finding in DD:</b> A reduced (less positive or more negative) rectoanal gradient during evacuation.</li><li>- A reduced gradient is <q>36% sensitive</q> and <q><b>85% specific</b></q> for predicting a prolonged BET.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Rectal Balloon Expulsion Test (BET)</strong></summary>
            <div>
                <ul><li>- Measures time to expel a balloon filled with 50 mL of warm water.</li><li>- A prolonged BET is a highly sensitive and specific index for diagnosing DD.</li><li>- A BET of <q><b>â‰¤60 seconds</b></q> is considered normal for most catheters.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Defecography (Fluoroscopic or MR)</strong></summary>
            <div>
                <ul><li>- Performed for inconclusive ARM/BET results or suspected structural abnormalities.</li><li>- Can reveal rectoceles, intussusception, or enteroceles.</li><li>- <b>Clinical Pearl:</b> Small rectoceles (<q><4 cm</q>) and intrarectal intussusception are common even in asymptomatic people.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- Requires a multidisciplinary approach focusing on improving symptoms and quality of life.</li></ul>
                
        <details>
            <summary><strong>Anorectal Biofeedback Therapy (BFT)</strong></summary>
            <div>
                <ul><li>- <u><b>Cornerstone</b></u> of managing DD.</li><li>- Effective in approximately <q><b>70%â€“80%</b></q> of patients in randomized trials.</li><li>- Superior to laxatives, sham therapy, and standard therapy.</li></ul>
                
        <details>
            <summary><strong>Mechanism & Practice</strong></summary>
            <div>
                <ul><li>- Involves coaching patients with visual feedback from electromyography or manometry (See Figure 3).</li><li>- Teaches patients to protrude the abdominal wall (diaphragmatic descent) while monitoring rectal pressure, aiming for <q>>45 mm Hg</q>.</li><li>- Includes abdominal breathing exercises and rectal sensory retraining for altered sensation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Availability</strong></summary>
            <div>
                <ul><li>- Demand for BFT far exceeds its availability in the US.</li><li>- Often provided by pelvic floor physical therapists, but only <q>50%</q> incorporate biofeedback techniques.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Predictors of Better Outcomes</strong></summary>
            <div>
                <ul><li>- Hard stools</li><li>- Anal digitation</li><li>- Strong patient engagement</li><li>- Prolonged BET</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adjunct & Refractory Management</strong></summary>
            <div>
                <ul><li>- Nonpharmacologic strategies are safe and likely beneficial.</li></ul>
                
        <details>
            <summary><strong>Lifestyle & Behavioral Strategies</strong></summary>
            <div>
                <ul><li>- Encourage adequate intake of fluids, calories, and fiber.</li><li>- Regular exercise.</li><li>- Heed the call to defecate promptly.</li><li>- Attempt defecation <q>30 minutes after breakfast</q> to utilize the gastrocolonic response.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of BFT-Refractory DD</strong></summary>
            <div>
                <ul><li>- Options are limited.</li><li>- Sacral neuromodulation (SNM) and pelvic floor injection of BT are <u><b>not effective</b></u>.</li><li>- Surgery may be considered for large, non-emptying rectoceles or enteroceles, but correcting structure does not always correct function.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fecal Incontinence (FI)</strong></summary>
            <div>
                <ul><li>- Defined as the unintentional loss of solid or liquid stool.</li><li>- Affects approximately <q><b>1 in 12 adults</b></q>.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Pathophysiology</strong></summary>
            <div>
                <ul><li>- More prevalent in people aged <q>>60 years</q> (<q>9.3%</q>) and in women (<q>9.1%</q>) than men (<q>7.4%</q>).</li></ul>
                
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- Continence is multifactorial, depending on motility, stool consistency, rectal function, and the anal barrier.</li><li>- Common dysfunctions: anal sphincter weakness, stiff/small rectum, altered rectal sensation.</li><li>- Leading risk factors in women: <q>aging and obstetric trauma</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Features & Investigations</strong></summary>
            <div>
                <ul><li>- Clinicians should assess severity, duration, risk factors, and impact on quality of life.</li><li>- A stool diary is more accurate than patient recall.</li></ul>
                
        <details>
            <summary><strong>Types of FI</strong></summary>
            <div>
                <ul><li>- <b>Urge FI:</b> Preserved (often increased) awareness before leakage; linked to rectal urgency.</li><li>- <b>Passive FI:</b> Occurs <u>without awareness</u>.</li><li>- Many patients have both types.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Investigations (See Figure 5)</strong></summary>
            <div>
                <ul><li>- A stepwise approach is recommended, starting with conservative therapy.</li><li>- Evaluate for diarrhea triggers (celiac disease, microscopic colitis, bile acid malabsorption).</li><li>- <b>ARM/BET:</b> Can identify anal weakness, DD, and rectal sensory disturbances to tailor BFT.</li><li>- <b>Endoanal Ultrasound/MR Imaging:</b> Can detect sphincter defects, scars, or atrophy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- Begins with conservative measures, escalating to BFT and then surgical options if needed.</li></ul>
                
        <details>
            <summary><strong>Diet, Lifestyle & Pharmacotherapy</strong></summary>
            <div>
                <ul><li>- Address modifiable risk factors: low fiber, bowel dysfunction, smoking, physical inactivity, increased BMI.</li></ul>
                
        <details>
            <summary><strong>Dietary Measures</strong></summary>
            <div>
                <ul><li>- <b>Psyllium <q>15 g/d</q></b> reduces loose or liquid FI compared with placebo.</li><li>- Limiting caffeine, alcohol, fatty foods, fructose, and lactose may be helpful.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pharmacotherapy</strong></summary>
            <div>
                <ul><li>- <b>Loperamide:</b> Increases stool consistency and anal pressure, slows transit.</li><li>- <b>Bile Acid Sequestrants:</b> Effective for diarrhea due to bile acid malabsorption.</li><li>- <b>Intrarectal Botulinum Toxin (200 U):</b> Reduced combined FI and urgency episodes vs placebo in urge-predominant FI.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Behavioral & Barrier Treatments</strong></summary>
            <div>
                <ul><li>- Focus on improving sphincter function and providing physical barriers.</li></ul>
                
        <details>
            <summary><strong>Biofeedback Therapy (BFT)</strong></summary>
            <div>
                <ul><li>- Aims to improve strength and endurance of anal sphincter contraction.</li><li>- More effective than pelvic floor exercises alone in patients unresponsive to initial therapy.</li><li>- In a large study, <q><b>two-thirds</b></q> of patients reported a â‰¥50% reduction in FI frequency at 6 weeks.</li><li>- Home-based BFT was not inferior to office-based therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Barrier Devices</strong></summary>
            <div>
                <ul><li>- Transanal irrigation may benefit patients with neurogenic bowel dysfunction.</li><li>- Newer anal and vaginal insert devices seem more effective than older plugs.</li><li>- An FDA-approved vaginal device led to a â‰¥50% reduction in FI in <q><b>70%</b></q> of users at 12 months.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surgical Options</strong></summary>
            <div>
                <ul><li>- Considered for refractory FI.</li></ul>
                
        <details>
            <summary><strong>Sacral Neuromodulation (SNM)</strong></summary>
            <div>
                <ul><li>- <u><b>Preferred surgical option</b></u>, especially with reduced anal contractility or overactive bladder.</li><li>- Long-term success (â‰¥50% reduction in FI episodes) is approximately <q><b>50%</b></q> at 5â€“10 years.</li><li>- Requires lifelong device management; surgical revision required in up to <q>one-third</q> of patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anal Sphincteroplasty</strong></summary>
            <div>
                <ul><li>- Typically reserved for younger women (<q><45 years</q>) with obstetric defects.</li><li>- Long-term 'good or excellent' continence rates are low (mean <q><b>38%</b></q>).</li><li>- Risks include wound infection/breakdown (<q>~20%</q>) and iatrogenic fistula (<q>~5%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Options</strong></summary>
            <div>
                <ul><li>- <b>Anal Dextranomer Injections:</b> Improve continence vs placebo, but <u>not</u> vs BFT.</li><li>- <b>Colostomy:</b> Remains an option for severe, refractory FI.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusions & Future Directions</strong></summary>
            <div>
                <ul><li>- Benign anorectal diseases are common and associated with bowel symptoms and/or anorectal sensorimotor dysfunctions.</li><li>- A stepwise approach is recommended, starting with simple treatments and escalating as needed.</li><li>- Surgery may be required for hemorrhoids, and less commonly for fissures and FI.</li></ul>
                
        <details>
            <summary><strong>Key Topics for Future Research</strong></summary>
            <div>
                <ul><li>- Clarify the natural history of these diseases.</li><li>- Define the role of DD in hemorrhoids and anal fissures.</li><li>- Devise more effective and accessible therapies (e.g., for fissures and DD).</li><li>- Evaluate long-term efficacy of stepwise treatments.</li><li>- Develop individualized therapies guided by predictive biomarkers.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
